Mark Peterson

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

With a former U.S. CTO, WHO expert, and life sciences vet, Welldoc is assembling a powerhouse team to dominate the AI-driven cardiometabolic care market.

As AI agents reshape e-commerce, a new HUMAN and AWS partnership aims to secure them with cryptographic verification, building a foundation for trusted automation.

New rankings name Germany's top cancer hospitals, but the real story is the rise of platforms shaping a multi-billion dollar global health market.

A new FDA clearance for its AI software enhances Hyperfine's portable MRI, positioning it to disrupt the lucrative stroke diagnostics market. Here's why.

The infrastructure giant's new €800M share repurchase isn't just for shareholder value; it's a strategic move to fund future growth and acquisitions.

Fairholme's year-end dividends are more than just income. We dissect the funds' high-risk, non-diversified strategy and what it means for investors.

Fresh off its IPO, iOThree is pushing AI and certified digital tools. Can its innovation engine and Asian expansion overcome market headwinds?

Predictive Oncology rebrands as Axe Compute, betting its future not on algorithms, but on solving the critical shortage of AI compute power. A deep dive.

After a painful restructuring, industrial manufacturer NN, Inc. is now exploring a sale. Is this the final step in its transformation or a capitulation?

Malaysia's Treasure Global secures fresh capital, but a brutal market reaction and high cash burn raise questions about its super app's future.

As John Lindsay retires, H&P anoints tech-savvy insider Trey Adams. A look at how this smooth transition secures a legacy of innovation.

As TD SYNNEX prepares its full-year report, the results will be a crucial test of its AI strategy and a key indicator for the entire IT ecosystem.

GoPro is turning user videos into a new revenue stream for the AI economy. Can this bold strategic shift save the company, or will it get lost in the ethical fog?

Inotiv partners with AI firm VUGENE, but this is no simple tech deal. It's a high-stakes move to compete in a market dominated by AI-powered giants.

Early results for INT230-6 show 50% fewer severe side effects, raising hopes for a treatment that could eliminate the toxic 'red devil' chemo.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

Xtant Medical's new nanOss Strata bone graft isn't just an update; it's a strategic move to disrupt the orthobiologics market. Here's why it matters.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.